financetom
Business
financetom
/
Business
/
Why Bitcoin-Related Stock BTC Digital Is Getting Hammered
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Bitcoin-Related Stock BTC Digital Is Getting Hammered
Dec 6, 2024 9:39 AM

BTC Digital Ltd ( BTCT ) shares are trading lower by 25.4% to $11.69 during Friday’s session after the company announced a $20 million public offering.

What Else: The offering includes 2.5 million ordinary shares and pre-funded warrants, priced at $8.00 per share or $7.999 per Pre-Funded Warrant, which have a nominal exercise price of $0.001 and are immediately exercisable.

Aegis Capital Corp. has a 45-day option to purchase up to 15% additional Ordinary Shares to cover potential over-allotments.

The offering is expected to close on December 9, pending customary conditions. Proceeds will support general corporate needs and working capital.

Read Also: Private Credit Tokenization Hits $650 Million Monthly, Setting A New Benchmark

Should I Sell My BTCT Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of BTC Digital ( BTCT ) have gained 258.84% year to date. This compares to the average annual return of 40.89%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. BTC Digital ( BTCT ) stock currently has an RSI of 46.72, indicating neutral conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

BTCT has a 52-week high of $25.40 and a 52-week low of $1.32.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brazil's Petrobras and miner Vale have decarbonization partnership in works
Brazil's Petrobras and miner Vale have decarbonization partnership in works
Oct 14, 2024
RIO DE JANEIRO (Reuters) - Brazil's Petrobras is discussing a partnership with Vale to help the mining company lower carbon emissions, the state-run oil firm's Chief Executive Magda Chambriard said on Monday. WHY IT'S IMPORTANT The two Brazilian companies are among the largest in Latin America by market value. Chambriard said the firms will help each other decarbonize, with a...
Shares of Trump Media extend huge comeback
Shares of Trump Media extend huge comeback
Oct 14, 2024
(Reuters) - Shares of former U.S. President Donald Trump's media company surged 17% on Monday, extending gains following a recent increase in betting odds that the Republican candidate will win the neck-and-neck race for the White House. Monday's gains in the shares of Trump Media & Technology Group ( DJT ), 57% owned by Trump, accelerated after reports that Democratic...
Stellantis on Pace to Fix US Sales Problems, CEO Reportedly Says
Stellantis on Pace to Fix US Sales Problems, CEO Reportedly Says
Oct 14, 2024
05:58 PM EDT, 10/14/2024 (MT Newswires) -- Stellantis ( STLA ) is sorting out its sales problems in the US at the right pace after a risky marketing plan in Q2 that didn't work, media reports on Monday said, citing Chief Executive Carlos Tavares. Speaking to reporters at the Paris Motor Show, Tavares also said the automaker's US problems should...
PTC Therapeutics Gets FDA Drug Review Date for Phenylketonuria Treatment
PTC Therapeutics Gets FDA Drug Review Date for Phenylketonuria Treatment
Oct 14, 2024
05:22 PM EDT, 10/14/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Monday the US Food and Drug Administration has set a target regulatory action date of July 29 to review its sepiapterin to treat pediatric and adult patients with phenylketonuria. The company said late Monday that the treatment is for all age groups and the full spectrum of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved